News

ASX Releases

Additional Data Released from Brain Metastases Imaging Trial

November 23, 2022

Read more Read more

RAD Agreement with ANSTO to supply key isotope lutetium-177

November 22, 2022

Read more Read more

Successful Completion of Retail Entitlement Offer

November 22, 2022

Read more Read more

Extension of Retail Entitlement Offer

November 8, 2022

Read more Read more

Update Proposed Issue of Securities

November 8, 2022

Read more Read more

AGM Attendance 8 Nov 2022

November 8, 2022

Read more Read more

Notification of Release of Shares from Escrow

November 8, 2022

Read more Read more

RAD Agreement with Northstar

October 26, 2022

Read more Read more

Successful Completion of Institutional Entitlement Offer

October 20, 2022

Read more Read more

Supplementary Prospectus

October 20, 2022

Read more Read more

Proposed Issue of Securities

October 19, 2022

Read more Read more

Prospectus 19 Oct 2022

October 19, 2022

Read more Read more

Entitlement Offer to Raise up to $10M

October 19, 2022

Read more Read more

Entitlement Offer Presentation

October 19, 2022

Read more Read more

Update Proposed Issue of Securities

October 19, 2022

Read more Read more

Pivalate Achieves Positive Phase 2 Data in Brain Mets Trial

October 18, 2022

Read more Read more

Presentation - Pivalate Achieves Positive Phase 2 Data

October 18, 2022

Read more Read more

Investor Webinar - Pivalate Positive Phase 2 Data

October 18, 2022

Read more Read more

NATURE publishes encouraging data on DUNP19 receptor role in cancer growth

October 4, 2022

Read more Read more

Ga68 - Integrin (RAD301) Selected for Presentation at EANM

September 27, 2022

Read more Read more

Pivalate Phase II Data to be Presented at October Conference in Barcelona

September 21, 2022

Read more Read more

RAD and SHIINE Supply Agreement for Cancer Fighting Isotope

September 20, 2022

Read more Read more

FDA Grants Rare Pediatric Disease Designation for RAD's DUNP19 for Osteosarcoma - revised

September 16, 2022

Read more Read more

MD Anderson and RAD Launch Joint Venture to Develop Novel Radiopharmaceuticals

September 14, 2022

Read more Read more

FDA Grants Orphan Drug Status for DUNP19 in Osteosarcoma

September 9, 2022

Read more Read more

Strategic Agreements with Lantheus and NanoMab

August 4, 2022

Read more Read more

Radiopharm Extends Agreement with GenesisCare for Australian Prostate Cancer Trial

July 1, 2022

Read more Read more

Dr Susann Brady-Kalnay appointed to RAD Scientific Advisory Board

June 21, 2022

Read more Read more

Investor Webinar - CEO and Riccardo Canevari and Dr Susann Brady-Kalnay to discuss promising radiopharmaceutical agent recently added to the RAD Portfolio

June 15, 2022

Read more Read more

Radiopharm and Isotopia announce supply agreement for Lutetium-177 N.C.A

June 14, 2022

Read more Read more

Radiopharm Adds Brain Tumor Technology To Portfolio

June 9, 2022

Read more Read more

Radiopharm Investor Presentation

June 9, 2022

Read more Read more

Radiopharm appoints Dr Leila Alland as Non-Executive Director

June 6, 2022

Read more Read more

Industry Leader Vittorio Puppo Joins RAD as COO

June 1, 2022

Read more Read more

Bioshares Summit 2022 Presentation

May 12, 2022

Read more Read more

RAD Licenses UCLA Dual Action Antibody

April 4, 2022

Read more Read more

RAD Dual Action Antibody Investor Deck

April 4, 2022

Read more Read more

Radiopharm Theranostics Investor Presentation

March 28, 2022

Read more Read more

Radiopharm signs LOI with GenesisCare to start first trial in Australia

March 23, 2022

Read more Read more

Hester Larkin appointed as Non-Executive Director

February 2, 2022

Read more Read more

Radiopharm and TerraPower sign supply agreement for Actinium-225

February 1, 2022

Read more Read more

RAD Acquires IP ownership of Radiopharmaceutical Nanobodies

January 24, 2022

Read more Read more

RAD to present at Biotech Showcase

January 10, 2022

Read more Read more

Radiopharm Expands Management Team with Three Senior Appointments

December 20, 2021

Read more Read more

Completion of Phase 1 Study in Breast Cancer

December 17, 2021

Read more Read more

Letter to Shareholders

December 10, 2021

Read more Read more

RAD's Integrins Technology featured in Cancers Journal

December 8, 2021

Read more Read more

Dr Hurvitz SAB Appointment

December 6, 2021

Read more Read more

ASX Investor Presentation 29 Nov 2021

November 29, 2021

Read more Read more

Radiopharm Theranostics Lists on the ASX After Raising $50M in IPO

November 25, 2021

Read more Read more

Radiopharm Theranostics’ Trivehexin (AVβ6-Integrin) published in European Journal of Nuclear Medicine

October 13, 2021

Read more Read more

European Molecular Imaging Meeting (EMIM) RAD301 Abstract

September 21, 2021

Read more Read more

RAD201 Published in peer reviewed Journal Molecular Pharmaceutics

September 15, 2021

Read more Read more

Radiopharm raise release FINAL

August 23, 2021

Read more Read more

RadioPharm and TRIMT

August 17, 2021

Read more Read more

MEDIA releases

GenesisCare and RAD Partner to Bring World First Novel Radiopharmaceuticals to Australian Cancer Patients

December 1, 2022

Read more Read more

CEO Interview series with Wholesale Investor

October 6, 2022

Read more Read more

RAD to Start Prostate Cancer Trial, Interview with Financial News Network

July 8, 2022

Read more Read more

World Congress Trivehexin Poster Presentation Shows Encouraging Integrin Data

June 28, 2022

Read more Read more

CEO Riccardo Canevari Updates Investors and Discusses Licensing of a Asset from UCLA

May 18, 2022

Read more Read more

Radiopharm Theranostics panel discusses latest progress and understanding of the radiopharmaceutical sector

May 9, 2022

Read more Read more

Radiopharm continues strong progress and recognition of AVβ6-Integrin in Europe

May 6, 2022

Read more Read more

CEO Riccardo Canevari visits Sydney and discusses the use of radiopharmaceuticals with Financial News Network

April 4, 2022

Read more Read more

Appointment of Bill Regan to Senior Vice President Regulatory Strategy

March 15, 2022

Read more Read more

Presentation at Financial News Network Investor Conference Feb 2022

February 24, 2022

Read more Read more

Paul Hopper speaks to Matt Birney from Bulls N' Bears

February 18, 2022

Read more Read more

RAD Expands Management Team with VP of Clinical Development Appointed

February 17, 2022

Read more Read more

Acceleration in Patient Recruitment with AVB6 - Integrin

February 11, 2022

Read more Read more

Bulls N' Bears Interview

November 29, 2021

Read more Read more

Radiopharm Theranostics makes its debut on the ASX as it develops its cancer killing technology

November 25, 2021

Read more Read more

Radiopharm Theranostics’ Founder Paul Hopper’s keynote address at Emerging Small Caps 2021 Summit

November 12, 2021

Read more Read more

Paul Hopper’s Radiopharm, Artrya pitch investors this week

October 11, 2021

Read more Read more

Entrepreneur Paul Hopper launches Radiopharm Theranostics following AU$20M Series A

September 17, 2021

Read more Read more

Radiopharm secures ex Novartis exec as CEO ahead of IPO

September 6, 2021

Read more Read more

Biotech veteran Paul Hopper taps Bell Potter and Baker Young for Radiopharma Theranostics pre-IPO

August 23, 2021

Read more Read more

News

ASX Releases

Additional Data Released from Brain Metastases Imaging Trial

RAD Agreement with ANSTO to supply key isotope lutetium-177

Successful Completion of Retail Entitlement Offer

Extension of Retail Entitlement Offer

Update Proposed Issue of Securities

AGM Attendance 8 Nov 2022

Notification of Release of Shares from Escrow

RAD Agreement with Northstar

Successful Completion of Institutional Entitlement Offer

Supplementary Prospectus

Proposed Issue of Securities

Prospectus 19 Oct 2022

Entitlement Offer to Raise up to $10M

Entitlement Offer Presentation

Update Proposed Issue of Securities

Pivalate Achieves Positive Phase 2 Data in Brain Mets Trial

Presentation - Pivalate Achieves Positive Phase 2 Data

Investor Webinar - Pivalate Positive Phase 2 Data

NATURE publishes encouraging data on DUNP19 receptor role in cancer growth

Ga68 - Integrin (RAD301) Selected for Presentation at EANM

Pivalate Phase II Data to be Presented at October Conference in Barcelona

RAD and SHIINE Supply Agreement for Cancer Fighting Isotope

FDA Grants Rare Pediatric Disease Designation for RAD's DUNP19 for Osteosarcoma - revised

MD Anderson and RAD Launch Joint Venture to Develop Novel Radiopharmaceuticals

FDA Grants Orphan Drug Status for DUNP19 in Osteosarcoma

Strategic Agreements with Lantheus and NanoMab

Radiopharm Extends Agreement with GenesisCare for Australian Prostate Cancer Trial

Dr Susann Brady-Kalnay appointed to RAD Scientific Advisory Board

Investor Webinar - CEO and Riccardo Canevari and Dr Susann Brady-Kalnay to discuss promising radiopharmaceutical agent recently added to the RAD Portfolio

Radiopharm and Isotopia announce supply agreement for Lutetium-177 N.C.A

Radiopharm Adds Brain Tumor Technology To Portfolio

Radiopharm Investor Presentation

Radiopharm appoints Dr Leila Alland as Non-Executive Director

Industry Leader Vittorio Puppo Joins RAD as COO

Bioshares Summit 2022 Presentation

RAD Licenses UCLA Dual Action Antibody

RAD Dual Action Antibody Investor Deck

Radiopharm Theranostics Investor Presentation

Radiopharm signs LOI with GenesisCare to start first trial in Australia

Hester Larkin appointed as Non-Executive Director

Radiopharm and TerraPower sign supply agreement for Actinium-225

RAD Acquires IP ownership of Radiopharmaceutical Nanobodies

RAD to present at Biotech Showcase

Radiopharm Expands Management Team with Three Senior Appointments

Completion of Phase 1 Study in Breast Cancer

Letter to Shareholders

RAD's Integrins Technology featured in Cancers Journal

Dr Hurvitz SAB Appointment

ASX Investor Presentation 29 Nov 2021

Radiopharm Theranostics Lists on the ASX After Raising $50M in IPO

Radiopharm Theranostics’ Trivehexin (AVβ6-Integrin) published in European Journal of Nuclear Medicine

European Molecular Imaging Meeting (EMIM) RAD301 Abstract

RAD201 Published in peer reviewed Journal Molecular Pharmaceutics

Radiopharm raise release FINAL

RadioPharm and TRIMT

MEDIA releases

GenesisCare and RAD Partner to Bring World First Novel Radiopharmaceuticals to Australian Cancer Patients

CEO Interview series with Wholesale Investor

RAD to Start Prostate Cancer Trial, Interview with Financial News Network

World Congress Trivehexin Poster Presentation Shows Encouraging Integrin Data

CEO Riccardo Canevari Updates Investors and Discusses Licensing of a Asset from UCLA

Radiopharm Theranostics panel discusses latest progress and understanding of the radiopharmaceutical sector

Radiopharm continues strong progress and recognition of AVβ6-Integrin in Europe

CEO Riccardo Canevari visits Sydney and discusses the use of radiopharmaceuticals with Financial News Network

Appointment of Bill Regan to Senior Vice President Regulatory Strategy

Presentation at Financial News Network Investor Conference Feb 2022

Paul Hopper speaks to Matt Birney from Bulls N' Bears

RAD Expands Management Team with VP of Clinical Development Appointed

Acceleration in Patient Recruitment with AVB6 - Integrin

Bulls N' Bears Interview

Radiopharm Theranostics makes its debut on the ASX as it develops its cancer killing technology

Radiopharm Theranostics’ Founder Paul Hopper’s keynote address at Emerging Small Caps 2021 Summit

Paul Hopper’s Radiopharm, Artrya pitch investors this week

Entrepreneur Paul Hopper launches Radiopharm Theranostics following AU$20M Series A

Radiopharm secures ex Novartis exec as CEO ahead of IPO

Biotech veteran Paul Hopper taps Bell Potter and Baker Young for Radiopharma Theranostics pre-IPO

Sign up to our mailing list.